GB0901423D0 - Treatment - Google Patents

Treatment

Info

Publication number
GB0901423D0
GB0901423D0 GB0901423A GB0901423A GB0901423D0 GB 0901423 D0 GB0901423 D0 GB 0901423D0 GB 0901423 A GB0901423 A GB 0901423A GB 0901423 A GB0901423 A GB 0901423A GB 0901423 D0 GB0901423 D0 GB 0901423D0
Authority
GB
United Kingdom
Prior art keywords
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GB0901423A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UK Secretary of State for Defence
Original Assignee
UK Secretary of State for Defence
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UK Secretary of State for Defence filed Critical UK Secretary of State for Defence
Priority to GB0901423A priority Critical patent/GB0901423D0/en
Publication of GB0901423D0 publication Critical patent/GB0901423D0/en
Application status is Ceased legal-status Critical

Links

GB0901423A 2009-01-29 2009-01-29 Treatment Ceased GB0901423D0 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB0901423A GB0901423D0 (en) 2009-01-29 2009-01-29 Treatment

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0901423A GB0901423D0 (en) 2009-01-29 2009-01-29 Treatment
PCT/GB2010/000146 WO2010086614A1 (en) 2009-01-29 2010-01-29 Treatment
GB201001517A GB2467436A (en) 2009-01-29 2010-01-29 Phosphoantigen for use in treatment of Burkholderia infection

Publications (1)

Publication Number Publication Date
GB0901423D0 true GB0901423D0 (en) 2009-03-11

Family

ID=40469227

Family Applications (2)

Application Number Title Priority Date Filing Date
GB0901423A Ceased GB0901423D0 (en) 2009-01-29 2009-01-29 Treatment
GB201001517A Withdrawn GB2467436A (en) 2009-01-29 2010-01-29 Phosphoantigen for use in treatment of Burkholderia infection

Family Applications After (1)

Application Number Title Priority Date Filing Date
GB201001517A Withdrawn GB2467436A (en) 2009-01-29 2010-01-29 Phosphoantigen for use in treatment of Burkholderia infection

Country Status (2)

Country Link
GB (2) GB0901423D0 (en)
WO (1) WO2010086614A1 (en)

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
SE8205892D0 (en) 1982-10-18 1982-10-18 Bror Morein Immunogenic membrane protein complex, seen for the front up and tell priority over derav as immune stimulant and as vaccine
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
EP0362278A4 (en) 1987-06-05 1990-05-14 Us Health Autocrine motility factors in cancer diagnosis and management.
US5278302A (en) 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5308854A (en) 1990-06-18 1994-05-03 Merck & Co., Inc. Inhibitors of HIV reverse transcriptase
EP0468520A3 (en) 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
US5192668A (en) 1990-10-11 1993-03-09 Merck & Co., Inc. Synthesis of protease inhibitor
US5187074A (en) 1990-10-11 1993-02-16 Merck & Co., Inc. Method of hydroxylation with ATCC 55086
WO1993008184A1 (en) 1991-10-23 1993-04-29 Merck & Co., Inc. Hiv protease inhibitors
US5413999A (en) 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
DK0671948T3 (en) 1992-06-25 1997-09-01 Smithkline Beecham Biolog A vaccine composition containing adjuvants
US5519021A (en) 1992-08-07 1996-05-21 Merck & Co., Inc. Benzoxazinones as inhibitors of HIV reverse transcriptase
DK0812593T4 (en) 1993-03-23 2008-05-13 Smithkline Beecham Biolog Vaccine preparations containing 3-O-deacylated monophosphoryl lipid-A
AU7973994A (en) 1993-10-13 1995-05-04 Merck & Co., Inc. Combination therapy for hiv infection
US6005099A (en) 1993-11-17 1999-12-21 Laboratoires Om S.A. Glucosamine disaccharides, method for their preparation, pharmaceutical composition comprising same, and their use
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
WO1995026204A1 (en) 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
US5476874A (en) 1994-06-22 1995-12-19 Merck & Co., Inc. New HIV protease inhibitors
CA2217178C (en) 1995-04-25 2009-09-29 Smithkline Beecham Biologicals S.A. Vaccines containing a saponin and a sterol
EP0761819A1 (en) * 1995-09-12 1997-03-12 BEHRINGWERKE Aktiengesellschaft Exopolysaccharides of burkholderia pseudomallei and burkholderia mallei
US5666153A (en) 1995-10-03 1997-09-09 Virtual Shopping, Inc. Retractable teleconferencing apparatus
US5846978A (en) 1996-05-02 1998-12-08 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
GB9620795D0 (en) 1996-10-05 1996-11-20 Smithkline Beecham Plc Vaccines
US6303347B1 (en) 1997-05-08 2001-10-16 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6764840B2 (en) 1997-05-08 2004-07-20 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
GB9711990D0 (en) 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
AU7924598A (en) 1998-06-08 1999-12-30 Sca Emballage France Fast flattening packaging
DE69935330T2 (en) 1998-06-30 2007-10-31 Om Pharma New acylated pseudodipeptides, method for the production thereof and pharmaceutical compositions containing thereof
FR2782721B1 (en) 1998-09-01 2000-11-03 Inst Nat Sante Rech Med Phosphohalohydrin new compounds, and method for making applications
US6558670B1 (en) 1999-04-19 2003-05-06 Smithkline Beechman Biologicals S.A. Vaccine adjuvants
CA2370697C (en) 1999-04-19 2012-03-06 Smithkline Beecham Biologicals S.A. Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide
WO2001046127A1 (en) 1999-12-22 2001-06-28 Om Pharma Acyl pseudopeptides bearing a functionalised auxiliary spacer
WO2003009855A2 (en) * 2001-07-20 2003-02-06 Bioagency Ag Organo-phosphorous compounds for activating gamma/delta t cells
US20070025960A1 (en) * 2003-05-16 2007-02-01 University Of Maryland Biotechnology Institute Bisphosphonates for prophylaxis and therapy against bioterrorism agents
WO2006067635A2 (en) * 2004-12-20 2006-06-29 Innate Pharma S.A. USE OF Ϝδ T LYMPHOCYTE ACTIVATORS AS VACCINE ADJUVANT
EA200702029A1 (en) 2005-03-22 2008-02-28 Иннейт Фарма NEW CLASS OF ACTIVATORS γ; δ T-CELLS AND THEIR APPLICATION
GB0519871D0 (en) * 2005-09-30 2005-11-09 Secr Defence Immunogenic agents
GB0615635D0 (en) * 2006-08-07 2006-09-13 Secr Defence Immunogenic proteins and uses thereof
US9297803B2 (en) * 2006-11-01 2016-03-29 Immport Therapeutics, Inc. Compositions and methods for immunodominant antigens
US20100189681A1 (en) * 2007-06-01 2010-07-29 Innate Pharma S.A. Methods of Using Phosphoantigens Together with Interleukin-2 for the Treatment of Cancer
EP2123285A1 (en) * 2008-05-21 2009-11-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Nucleosidic phosphoantigens for use in VGAMMA9DELTA2 T cell-mediated therapy

Also Published As

Publication number Publication date
GB2467436A (en) 2010-08-04
GB201001517D0 (en) 2010-03-17
WO2010086614A1 (en) 2010-08-05

Similar Documents

Publication Publication Date Title
GB0919432D0 (en) Use
GB0910545D0 (en) Picturesafe
HK1166333A1 (en) Anti-bcma antibodies -bcma
EP2488033A4 (en) Combination
EP2415386A4 (en) Endoscope
EP2462514A4 (en) Greenbooks
GB0902393D0 (en) Elaectric machine - modular
EP2515891A4 (en) 3-keto-n-propargyl-1-aminoindan
HK1175476A1 (en) Cancer treatment
EP2380483A4 (en) Endoscope
PL2443485T3 (en) Biomedical devices
GB0802116D0 (en) Treatment
GB201003863D0 (en) Spectropotometer
EP2405869A4 (en) Obesity treatment
PL2443486T3 (en) Biomedical devices
GB0905568D0 (en) Taxling
HK1163005A1 (en) Tricyanoborates
ZA201108637B (en) Pyrazinylpyrazoles
HK1171017A1 (en) Quinolinyloxyphenylsulfonamides
GB0823213D0 (en) Treatment
PL2464939T3 (en) Improved workpiece-carrier
EP2404541A4 (en) Endoscope
GB0915552D0 (en) Cable-routing
GB0904835D0 (en) Trailersafe
EP2493820A4 (en) Water treatment

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)